Compare Gap Inc (GAP) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Gap Inc trades at $22.66 (market cap $8.02B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Gap Inc and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Gap Inc pays a 3.07% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GAP | SYRE | |
|---|---|---|
Market Cap | $8.02B | $7.52B |
Volume | 4,496,595 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $108.92 |
52-Week Low | $18.35 | $22.18 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $11.25B | $6.52B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $22.67, down 0.48% on the day, with a bullish technical signal supported by strong moving averages. The company shows improving fundamentals with revenue growth to $15.09B in 2025 and net income margin expanding to 8.14%. Recent strategic moves include music partnerships and board appointments, while analyst consensus targets $25.67 with 31% buy ratings.
The outlook remains positive with projected 2026 revenue of $15.3B and net income of $1.2B, though risks include Old Navy's sales decline and competitive pressures. Valuation appears attractive with P/E of 6.88 and P/S of 0.56, suggesting potential upside to consensus targets if execution continues.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
